The Marked Chart Wire · Series of events
Series of events · CRISPR Therapeutics
CRISPR Therapeutics reports sales, designations and trial data
The gene editing company reports third quarter sales, FDA designations for a heart drug and early trial results for a rare disease therapy.
Updated
The flow in 3 points
- CASGEVY sales reached $99 million in the third quarter
- CTX310 received FDA designations for heart disease
- 83 percent of systemic sclerosis patients reached a target
What happened, in order
Times are Eastern-
Where it began
Heart drug potential noted
CTX310 is viewed as having a larger market opportunity than the approved product Casgevy.
Read the story -
Sales and designations reported
The company reported $99 million in CASGEVY sales and received FDA designations for CTX310.
Read the story -
Latest
Rare disease trial data posted
Early results showed 83 percent of systemic sclerosis patients reached a target with zugo-cel.
Read the story
How they connect
The company first highlighted the market potential of its heart disease candidate CTX310. It then reported third quarter sales and FDA designations for that candidate, followed by early trial results for a separate rare disease therapy.
The stocks in this series
Prices from Before the open · based on Fri close · Opens 9:30 AM ET. Each tile opens the stock's chart and news.
A series is a short summary of connected news, for learning. Not verified and not advice. Check the full stories before you act.